melanoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
melanoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
melanoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Determinants of BRAF mutations in primary melanomas.
|
14679157 |
2003 |
melanoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
|
22048237 |
2012 |
melanoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
Thyroid Neoplasm
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Gastric Adenocarcinoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Cutaneous Melanoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Noonan Syndrome
|
|
0.700 |
CausalMutation
|
CLINVAR |
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
|
19206169 |
2009 |
Chronic Lymphocytic Leukemia
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Noonan Syndrome
|
|
0.700 |
CausalMutation
|
CLINVAR |
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
|
23026937 |
2013 |
Malignant Uterine Corpus Neoplasm
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
THYROID CANCER, NONMEDULLARY, 2
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
Adenocarcinoma of lung (disorder)
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Noonan Syndrome
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
|
16953233 |
2007 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
Adenocarcinoma of prostate
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Noonan Syndrome
|
|
0.700 |
CausalMutation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
The patients with BRAF K601E- and T599_V600insAGA-mutated tumors had similar clinicopathologic features to those with BRAF V600E-mutated tumors.
|
29037218 |
2017 |
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
We confirmed the presence of RAS mutations and BRAF K601E mutation in benign, borderline, and malignant follicular-patterned tumors.
|
29723601 |
2018 |
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
Cytology was consistent with "follicular neoplasia" (negative for galectin-3 immunostaining); molecular analysis on the cytology sample detected a K601E mutation in the exon 15 of the BRAF gene.
|
22136270 |
2011 |
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively).
|
26643848 |
2016 |
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
This technique, together with an earlier described real-time test specific for V600E and K601E will be useful for research and molecular diagnostic laboratories involved in the study of BRAF-related neoplasia.
|
20186005 |
2010 |
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
The tumor was found to be BRAF mutation positive (K601E).
|
20718682 |
2010 |